SG10201906329VA - Prohemostatic proteins for the treatment of bleeding - Google Patents

Prohemostatic proteins for the treatment of bleeding

Info

Publication number
SG10201906329VA
SG10201906329VA SG10201906329VA SG10201906329VA SG10201906329VA SG 10201906329V A SG10201906329V A SG 10201906329VA SG 10201906329V A SG10201906329V A SG 10201906329VA SG 10201906329V A SG10201906329V A SG 10201906329VA SG 10201906329V A SG10201906329V A SG 10201906329VA
Authority
SG
Singapore
Prior art keywords
bleeding
treatment
proteins
prohemostatic
subject
Prior art date
Application number
SG10201906329VA
Other languages
English (en)
Inventor
Daniël Verhoef
Pieter H Reitsma
Mettine H A Bos
Original Assignee
Academisch Ziekenhuis Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academisch Ziekenhuis Leiden filed Critical Academisch Ziekenhuis Leiden
Publication of SG10201906329VA publication Critical patent/SG10201906329VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG10201906329VA 2014-05-26 2015-05-26 Prohemostatic proteins for the treatment of bleeding SG10201906329VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14169895 2014-05-26

Publications (1)

Publication Number Publication Date
SG10201906329VA true SG10201906329VA (en) 2019-08-27

Family

ID=50774744

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201906329VA SG10201906329VA (en) 2014-05-26 2015-05-26 Prohemostatic proteins for the treatment of bleeding
SG11201609811TA SG11201609811TA (en) 2014-05-26 2015-05-26 Prohemostatic proteins for the treatment of bleeding

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201609811TA SG11201609811TA (en) 2014-05-26 2015-05-26 Prohemostatic proteins for the treatment of bleeding

Country Status (24)

Country Link
US (4) US10537618B2 (ru)
EP (2) EP3149163B1 (ru)
JP (3) JP6640198B2 (ru)
KR (2) KR102351728B1 (ru)
CN (1) CN106536566A (ru)
AU (2) AU2015268149B2 (ru)
CA (1) CA2949349A1 (ru)
DK (1) DK3149163T3 (ru)
EA (2) EA037991B1 (ru)
ES (1) ES2813440T3 (ru)
HR (1) HRP20201311T1 (ru)
HU (1) HUE052098T2 (ru)
IL (2) IL249132B (ru)
LT (1) LT3149163T (ru)
MA (2) MA40042B1 (ru)
MX (2) MX2016015567A (ru)
NZ (2) NZ764611A (ru)
PL (1) PL3149163T3 (ru)
PT (1) PT3149163T (ru)
RS (1) RS60706B1 (ru)
SG (2) SG10201906329VA (ru)
SI (1) SI3149163T1 (ru)
WO (1) WO2015183085A1 (ru)
ZA (1) ZA201608017B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3149163T (pt) 2014-05-26 2020-09-03 Academisch Ziekenhuis Leiden Proteínas proemostáticas para o tratamento de hemorragia
CN108486197B (zh) * 2018-03-06 2021-10-22 爱斯特（成都）生物制药股份有限公司 高纯度依度沙班中间体的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
WO1992009698A1 (en) 1990-11-26 1992-06-11 Genetics Institute, Inc. Expression of pace in host cells and methods of use thereof
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
DE4203965A1 (de) 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
AT404357B (de) 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
DE19605126A1 (de) 1996-02-12 1997-08-14 Basf Ag Thrombinmuteine als Antidot für Thrombininhibitoren
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
MX2008006313A (es) * 2005-11-15 2008-11-06 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (en) * 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
WO2008127702A2 (en) * 2007-04-13 2008-10-23 Catalyst Biosciences, Inc. Modified factor vii polypetides and uses thereof
SG185263A1 (en) * 2007-09-28 2012-11-29 Portola Pharm Inc Antidotes for factor xa inhibitors and methods of using the same
TWI465247B (zh) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
CN102625712B (zh) 2009-07-15 2017-07-25 博尔托拉制药公司 用于因子xa抑制剂的解毒剂的单位剂量制剂及其使用方法
MX365612B (es) * 2012-07-25 2019-06-07 Catalyst Biosciences Inc Polipeptidos de factor x modificados y usos de los mismos.
WO2014118677A1 (en) 2013-01-31 2014-08-07 Pfizer Inc. Compositions and methods for counteracting factor xa inhibition
US10119101B2 (en) 2014-04-28 2018-11-06 Ecolab Usa Inc. Method of minimizing enzyme based aerosol mist using a pressure spray system
PT3149163T (pt) * 2014-05-26 2020-09-03 Academisch Ziekenhuis Leiden Proteínas proemostáticas para o tratamento de hemorragia

Also Published As

Publication number Publication date
ZA201608017B (en) 2019-04-24
RS60706B1 (sr) 2020-09-30
PL3149163T3 (pl) 2020-12-28
WO2015183085A1 (en) 2015-12-03
US10537618B2 (en) 2020-01-21
AU2021203838B2 (en) 2023-03-02
JP2017522900A (ja) 2017-08-17
US11357836B2 (en) 2022-06-14
SG11201609811TA (en) 2016-12-29
EA201692161A1 (ru) 2017-08-31
KR20170020332A (ko) 2017-02-22
NZ764611A (en) 2024-07-05
EP3149163B1 (en) 2020-06-03
ES2813440T3 (es) 2021-03-23
LT3149163T (lt) 2020-09-25
AU2021203838A1 (en) 2021-07-08
NZ727444A (en) 2021-12-24
US20200138916A1 (en) 2020-05-07
CA2949349A1 (en) 2015-12-03
MX2020013410A (es) 2021-02-26
JP2022134139A (ja) 2022-09-14
MA40042B1 (fr) 2020-08-31
MX2016015567A (es) 2017-06-29
JP2020062039A (ja) 2020-04-23
KR102351728B1 (ko) 2022-01-14
JP7535849B2 (ja) 2024-08-19
SI3149163T1 (sl) 2020-10-30
HUE052098T2 (hu) 2021-04-28
US11304995B2 (en) 2022-04-19
EA037991B1 (ru) 2021-06-21
PT3149163T (pt) 2020-09-03
EA202190813A1 (ru) 2021-12-31
HRP20201311T1 (hr) 2020-12-11
BR112016027649A2 (pt) 2017-08-15
US20170157223A1 (en) 2017-06-08
EP3744840A1 (en) 2020-12-02
US20220288172A1 (en) 2022-09-15
IL277377B (en) 2021-10-31
EP3149163A1 (en) 2017-04-05
US12083170B2 (en) 2024-09-10
US20200138917A1 (en) 2020-05-07
IL249132A0 (en) 2017-01-31
MA51688A (fr) 2020-12-02
DK3149163T3 (da) 2020-08-31
IL249132B (en) 2020-09-30
KR20210054573A (ko) 2021-05-13
AU2015268149B2 (en) 2021-03-11
AU2015268149A1 (en) 2016-12-08
JP6640198B2 (ja) 2020-02-05
KR102245264B1 (ko) 2021-04-28
CN106536566A (zh) 2017-03-22
IL277377A (en) 2020-11-30

Similar Documents

Publication Publication Date Title
PH12018500057A1 (en) Substituted oxopyridine derivatives
MX2018007703A (es) Inhibidores de la interaccion de menina-linaje leucemico mixto.
MY182667A (en) Food compositions comprising one or both of recombinant beta-lactoglobulin protein and recombinant alphalactalbumin protein
WO2017015622A3 (en) Gdf11 binding proteins and uses thereof
MX2021013665A (es) Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.
EP3267792A4 (en) Compositions for use in treating pulmonary arterial hypertension
NZ773116A (en) Bicyclic heterocycles as fgfr inhibitors
EA201791775A1 (ru) Цистеиновая протеаза
MX2017016345A (es) Proteinas de fusion para inhibir la angiogenesis.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201790380A1 (ru) Ингибиторы mk2 и их применения
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201692552A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
SI3197472T1 (sl) Rekombinantni proteini brez PHE za uporabo pri zdravljenju fenilketonurije
EA201691429A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
WO2014159669A3 (en) Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions
WO2016007540A3 (en) Compositions and methods for treating dengue virus infection
MX359029B (es) Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -.
MX2020013410A (es) Proteinas prohemostaticas para el tratamiento de hemorragias.
MX2018007468A (es) Composiciones de colageno 7 y metodos para usar las mismas.
PH12016501608A1 (en) Peptides and methods of use
WO2016025533A3 (en) Compositions and methods for treating synucleinopathies
WO2015191636A3 (en) Xanthine oxidase inhibitors and methods of use